UBS Group AG Has $4.09 Million Stock Position in NeoGenomics, Inc. $NEO

UBS Group AG decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 56.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 347,574 shares of the medical research company’s stock after selling 456,676 shares during the quarter. UBS Group AG owned about 0.27% of NeoGenomics worth $4,087,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Aberdeen Group plc increased its position in shares of NeoGenomics by 91.8% during the 3rd quarter. Aberdeen Group plc now owns 792,263 shares of the medical research company’s stock worth $6,116,000 after purchasing an additional 379,165 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of NeoGenomics during the 3rd quarter worth approximately $1,281,000. Greenhouse Funds LLLP increased its position in shares of NeoGenomics by 10.6% during the 3rd quarter. Greenhouse Funds LLLP now owns 8,220,657 shares of the medical research company’s stock worth $63,463,000 after purchasing an additional 789,510 shares during the last quarter. Silverback Asset Management LLC acquired a new position in shares of NeoGenomics during the 3rd quarter worth approximately $1,554,000. Finally, White Pine Capital LLC increased its position in shares of NeoGenomics by 394.3% during the 3rd quarter. White Pine Capital LLC now owns 138,822 shares of the medical research company’s stock worth $1,072,000 after purchasing an additional 110,735 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on NEO shares. Weiss Ratings lowered NeoGenomics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Leerink Partners raised NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $12.00 to $25.00 in a research report on Wednesday, April 29th. Piper Sandler lifted their target price on NeoGenomics from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 24th. Zacks Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 20th. Finally, Benchmark upgraded NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Wednesday, April 29th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $13.86.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $9.23 on Friday. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. NeoGenomics, Inc. has a 12 month low of $4.72 and a 12 month high of $13.74. The stock has a 50 day moving average of $8.27 and a 200-day moving average of $10.30. The company has a market capitalization of $1.20 billion, a P/E ratio of -11.99 and a beta of 1.81.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, April 28th. The medical research company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The company had revenue of $186.67 million during the quarter, compared to the consensus estimate of $184.54 million. NeoGenomics’s quarterly revenue was up 11.3% compared to the same quarter last year. As a group, equities research analysts predict that NeoGenomics, Inc. will post -0.15 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.